title: Antibody-targeted nanoparticles for cancer therapy.
abstract: In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, in particular antibodies. Antibody-nanoparticle conjugates have the potential to elicit effective targeting and release of therapeutic targets at the disease site, while minimizing off-target side effects caused by dosing of normal tissues. This article provides an overview of various antibody-conjugated nanoparticle strategies, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.
authors.affiliation: Queen's University Belfast, Medical Biology Centre, Belfast, BT9 7BL, UK.
authors.forename: Francois
authors.initials: F
authors.lastname: Fay
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Scott
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D050091:Dendrimers / Q000737:chemistry / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008081:Liposomes / Q000737:chemistry / Q000627:therapeutic use; D051379:Mice; D008823:Micelles; D050997:Nanomedicine / Q000379:methods* / Q000639:trends; D049329:Nanostructures / Q000737:chemistry / Q000627:therapeutic use; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D011956:Receptors, Cell Surface / Q000737:chemistry / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D050091:Dendrimers; D008081:Liposomes; D008823:Micelles; D011956:Receptors, Cell Surface